Cardiff Oncology Inc.

CRDF | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.37

$0 (0.00%)

At close: Sep 21, 2026, 4:00 PM ET

$1.34

-$0.03 (-2.19%)

Pre-market: Sep 22, 2026, 8:09 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Aug 31, 2026

30.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $105.59M

1D Range

1.37 1.41

52W Range

0.76 3.31

Valuation (TTM)

PE -2.28

PB 3.98

EV/EBITDA -1.84

Valuation (NTM)

Forward PE N/A

Forward PEG -0.42

Price Target $2

Cash Flow

FCF Yield -38.8%

SBC Adj. FCF Yield -43.7%

SBC Impact -12.8%

Margins

Gross Margin 100.0%

Operating Margin -8320.1%

FCF Margin -8054.3%

Growth (CAGR)

Revenue 3Y | 5Y 7.2% | 5.2%

Dil EPS 3Y | 5Y 18.6% | 5.2%

FCF 3Y | 5Y -11.0% | -8.2%

Returns

ROA -107.3%

ROE -103.1%

ROIC -156.6%

Financial Health

Net Cash

$34.52M

Current Ratio 3.30

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and ...

Sector Healthcare

Industry Biotechnology

Employees 31

IPO Date Jul 26, 2004

Website www.cardiffoncology.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Upside

+45.99%

Buy (2)

Hold (3)

Sell (0)

Analyst Details ➞